Send better emails
MailCharts puts competitor emails and actionable data all in one place, so you can keep your inbox clutter-free. Learn more
From Novartis Release <media.relations@novartis.com>
Friday, Feb 28th, 2025 at 7:43 am
Subject: Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
Preview text: Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the
Recent emails from Novartis
